Introduction
Heparin is commonly used to treat various conditions found that body weight was a significant determinant of the infusion dosage requirement,12,14 while others including venous thromboembolism and coronary found that there was no significant correlation artery disease, or as temporary anticoagulation in between body weight, age, gender and the dose rheumatic atrial fibrillation and metallic valvular required to keep the therapeutic APTT between 1.5 replacement when an operation is contemplated. to 2.5 times of control. 15 The correct dosing of Both intravenous and subcutaneous routes are used, heparin is obviously important for drug efficacy and though the former can achieve a faster plasma level safety, since subtherapeutic doses will be associated with a smaller total daily dose.1 In Caucasians, the with a higher incidence of recurrent thrombosis, recommended initial heparin infusion dose ranges while over-anticoagulation will increase the risk of from 1000 to 1700 units/h, to maintain the activated bleeding complications. Therefore, we studied the partial thromboplastin time (APTT) at 1.5-2.5 of correct infusion dose for heparin, and its determincontrol value.2-7 The calculated mean infusion dose ants, in Chinese patients. This information is required is 1200-1500 units/h in different studies. 1, [8] [9] [10] [11] [12] to produce guidelines for starting intravenous heparin However, whether Chinese patients require the same infusion in Chinese patients so that faster and safer infusion dose for the same degree of anticoagulation anticoagulation control can be achieved. is not clear. Recently we have shown that Chinese required a much lower maintenance dose of warfarin than Caucasians patients for the same intensity of Methods anticoagulation.13 However, there is no information about heparin requirements in Chinese patients.
Between July and December 1994, we studied 100 Chinese patients admitted to the general medical In Caucasian subjects, Rashke and Gunnarsson wards of the Prince of Wales Hospital who required height was 161.0±8.2 cm. As expected, men were heavier than women (61.0±10.1 vs. 52.0±9.6 kg, heparin therapy. Potential study patients were identified from the registry of requests for APTT and were p<0.0001). The main indications for heparin therapy included chronic rheumatic heart disease (32%), reviewed by one investigator (CMY). As there was no fixed protocol for the initiation of anticoagulation, heart valve replacements (23%), deep-vein thrombosis and/or pulmonary embolism (24%), ischaemic the physicians were free to start heparin therapy by their preferred regimes. Only those patients put on heart disease (9%), cerebrovascular accident/transient ischaemic attack (8%), other arterial embolization intravenous heparin in whom the therapeutic APTT was planned to be 1.5 to 2.5 times baseline value (3%), and lone atrial fibrillation (1%). The mean baseline APTT was 32.6±4.7 s. were selected. Most (62%) were given 5000 units as a bolus i.v., but the remainder of the dose ranged
The mean therapeutic infusion dose requirement of heparin was 848.7±274.7 units/h (range 300 to from 2000 to 6000 units. Various intravenous infusion doses followed. The APTT was regularly mon-1700 units/h), and 79% required a dose of 1000 units/h or less. Men needed a significantly higher itored up to four times daily and the dose of heparin was adjusted by the attending physician liberally infusion dose than women (949.8±271.4 vs. 745.2±239.6 units/h, p=0.0004). according to the APTT result. The mean therapeutic dose requirement was defined as the dose associated There was a negative correlation between the age of the patient and the heparin requirement (r= with the greatest number of therapeutic APTT values, at least two of which were consecutive and after a −0.40, p<0.001) (Figure 1 ). Multiple regression analysis revealed that age ( p= 0.01), body weight ( p=0.003) and height ( p= Case notes were reviewed and the following information noted: age, sex, body weight, height, 0.049) were significant independent determinants of heparin requirement in the total study population indication for heparin therapy, concomitant medical conditions and medications, and relevant laborat-( Table 1 ). The other significant factors were albumin level ( p=0.0006) and number of medications that ory data.
Venous blood samples were collected in which the patient was taking ( p=0.03). Patients with higher serum albumin required a lower infusion dose of 2.25 ml of blood was mixed with 0.25 ml 0.109 M trisodium citrate dihydrate and centrifuged at 1500 g heparin. Commonly-taken drugs included diuretics in 31%, angiotensin-converting enzyme inhibitors in for 15 min. APTTs were measured on the plasma using an automated coagulometer ACL 100 22%, and aspirin in 11%. The number of medications taken by the patients were: none, 20%; one, 21%; (Instrumentation Laboratory, Milano, Italy) which employed nephelometry to detect the end point for two, 13%; three, 20%; four, 13%; five or more, 13%. Other covariates, including the gender of the clot detection. Commercial reagent, Automated APTT (Organon Teknik, Durham, North Carolina, USA), patient, the presence of liver disease (defined as raised bilirubin and transaminase biochemically with was used as the source of contact factors activator and phospholipid.
or without clinical jaundice) or right heart failure (defined as the presence of ankle oedema, raised All the data are expressed as means±SD. The relationship between variables was evaluated using jugular venous pressure, pulsatile liver, tricuspid regurgitation murmur) and the indication of anticoaglinear regression analysis. The relative importance of various factors as the determinants of heparin infuulation therapy, were not important. sion dose requirements was evaluated by multiple regression analysis. The difference in heparin requirement between genders was assessed by Student's t Discussion test. p<0.05 was considered statistically significant.
In this study, we have demonstrated that Chinese patients need an average therapeutic infusion dose of heparin of about 850 units/h. This dose is lower
Results
than most of the reports of Caucasians, in whom the requirement mostly was between 1200-1500 units/h A total of 100 Chinese patients (46 men and 53 women) were studied. Their mean age was (Tables 2 and 3 ). However, Gunnarsson12 and Holm16 described that a lower average therapeutic heparin 52.2±13.0 years (range 29-79 years). The mean body weight was 56.2±10.8 kg, and their mean dose (1092 and 1032 units/h, respectively). Although body weight is not available in most of the Caucasian factors contribute. Since heparin is internalized and depolymerized by the endothelial cells, or taken up reports, those available indicate that our Chinese subjects are much lighter than Caucasians.12, 14, 16, 17 by the mononuclear cells,2,21,22 it is unlikely to be explained by possible differences in the liver metaOn a weight-to-weight basis, the dose requirement in our study is 15 units/kg, while Caucasians required bolism or renal clearance in different ethnic groups. Whether Chinese are genetically more sensitive to 13-17 units/kg. The apparent difference in dose requirement can thus largely be explained by body the heparin-antithrombin complex mediated inactivation of clotting factors remains to be determined by weight. According to the multiple regression coefficient obtained in our study (Table 1) , if Chinese further studies. Our finding has considerable clinical importance when heparin therapy is initiated in patients achieved about the same body weight as Caucasians (about 20 kg more), the dose required Chinese patients, since the present recommended regime is likely to render patients overwould be 176 units/day more, making the mean dose requirement 1024 units/day, which is similar anticoagulated, which may lead to bleeding complications. to the recommended dose of 1000 units/day for Caucasian patients. However, other Caucasian It has been observed for decades that there is a large inter-individual variation in the anticoagulation reports recommend an initial infusion dose of 1400 units/day after the bolus dose.6,18,19 In addition, in response to heparin, although the possible factors have not been investigated comprehensively. We most of the Caucasian reports which suggest a much bigger maintenance heparin dose requirement of found a positive correlation between body weight and heparin maintenance infusion dose requirement, >1300 units/h, mean body weight is not available. 1, 8, 11, 15, 20 If body weight has not changed in the consistent with Gunnarsson's12 and Rashke's14 findings, although another smaller-scale study showed past decade, then other factors may be responsible for the observed larger heparin dose requirement in no significant correlation.15,23 The increased dose requirement is probably due to the larger intravascuCaucasian patients apart from body weight. In addition, if the age of patients in our study is compared lar volume, as the volume of distribution of heparin is mainly that of the plasma.7,19 with those from Caucasian studies in which a relatively lower mean heparin infusion dose was With increasing age, our maintenance heparin requirement decreased, and this correlation was still reported,12,16,20 patients in our study are about 10 years younger. Therefore, from the regression coeffisignificant after multiple regression. This contrasts to other studies in which age was not an important cient obtained (Table 1) , our patients might require 57 units/day less if a group of patients with similar determinant.15,23 Although both Raschke14 and Holm16 found that older patients tended to require age to these Caucasians was studied.
The reason for the remaining observed net differa lower dose, no statistical tests were performed. The reason for a decrease in heparin requirement ence in heparin requirement is not known. It is possible that pharmacokinetic or pharmacodynamic with increasing age is not fully understood. Although 
There is a large intra-individual variation in hepresult in heparin, as its clearance is influenced by the level of circulating anti-heparin and its binding arin response. Such variation can be one of the main reasons for difficulties in adjusting the correct infuto the saturable sites on the endothelial cells. Similarly, the maintenance dose requirement of oral sion dose of heparin in some patients and reaching a therapeutic APTT. The reason for such a variation anticoagulant (warfarin) requirement also decreases with increasing age in both Chinese13 and Caucasians in heparin response is unknown. It is known that the dose-response curve of heparin is not linear but is patients,25,26 which may be related more to pharmacodynamic than pharmacokinetic factors. A exponential, as illustrated in one of our patients (Figure 4) . The anticoagulant response increases disdecrease in functional liver mass in elderly may be important in the dosage of warfarin27 although this proportionally in intensity and duration (longer halflife) as the dose increases.31 As a result, the calculated has not been determined for heparin. The exact mechanism still requires investigation. In view of the heparin dose index may increase within the same individual when the infusion dose is increased. separate effect of age and body weight, we have constructed a table to provide guidelines for heparin However, this cannot account for the variation in the index when the same infusion dose is repeated. dosage at the start of the infusion (Table 4) .
In our patients, higher serum albumin lowered the There may also be non-biological causes of day-today variation,32 such as inaccuracy of the roller heparin requirement. Heparin binds to many plasma proteins after injection. In uraemic patients underclamp system of infusion, the choice of infusion pump, and delay in the laboratory assay of APTT. going haemodialysis, there was a negative correlation between serum albumin and heparin requirements.28
There has been a steady move to the use of lowmolecular-weight heparins (LMWHs) in patients with In vitro studies have shown that albumin possesses a heparin-like activity, which enhances the antiacute venous thromboembolism. LMWHs differ from the conventional, unfractionated heparin in a number Factor X a activity of antithrombin III, that is independent of and additive to heparin activities.29 Patients of characteristics, which is probably due to differences in molecular weight distribution.33 The better with nephrotic syndrome had no measurable heparin activity, which is present in healthy persons.29 subcutaneous bioavailability and longer biological half-life allows once-daily administration and even Although heparin also binds to albumin, the heparinalbumin complex had the same anticoagulant and home therapy for selected patients. 34 LMWHs are more likely to be effective in preventing recurrent aggregating effect as heparin in vitro.30 Another contributing factor may be heparin inhibition of venous thromboembolism, produce less major bleeding, and are associated with a lower mortality rate.35 protein synthesis.
Gender did not significantly affect heparin requireAlthough laboratory monitoring is considered unnecessary,33 some investigators did adjust the dose to ment in our study. This is consistent with other results.14,15 The larger mean dose requirement in target a given anti X a activity in the treatment of but, doses will need to be increased with larger body 
